Mono Pharmacare (NSE:MONOPHARMA) Retained Earnings: ₹0 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
11 GF Score
Price ₹8.95
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Retained Earnings?

Mono Pharmacare NSE:MONOPHARMA +4.68% 11 Retained Earnings is ₹0 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Mono Pharmacare's retained earnings for the quarter that ended in Sep. 2025 was ₹0 Mil.

Mono Pharmacare's quarterly retained earnings increased from Sep. 2024 (₹0 Mil) to Mar. 2025 (₹61 Mil) but then declined from Mar. 2025 (₹61 Mil) to Sep. 2025 (₹0 Mil).

Mono Pharmacare's annual retained earnings increased from Mar. 2023 (₹5 Mil) to Mar. 2024 (₹30 Mil) and increased from Mar. 2024 (₹30 Mil) to Mar. 2025 (₹61 Mil).


Mono Pharmacare  (NSE:MONOPHARMA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Mono Pharmacare Retained Earnings Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Retained Earnings Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Retained Earnings
0.00 0.00 5.35 29.84 60.74

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Retained Earnings Get a 7-Day Free Trial Premium Member Only 0.00 29.84 0.00 60.74 0.00
NSE:MONOPHARMA
11GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹0 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Retained Earnings of ₹0 Mil as of Sep. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Mono Pharmacare and its competitors.
Is Mono Pharmacare's Retained Earnings too high?
Mono Pharmacare's current Retained Earnings is ₹0 Mil. Overall, Mono Pharmacare has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Retained Earnings compare to competitors?
Mono Pharmacare's Retained Earnings of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Healthcare Providers & Services company?
A good Retained Earnings depends on the Healthcare Providers & Services industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Retained Earnings is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Retained Earnings of ₹0 Mil. The current Retained Earnings is ₹0 Mil. Mono Pharmacare's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Retained Earnings is ₹0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
11GF Score

Get the complete analysis for NSE:MONOPHARMA

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8.95
Price